Fujirebio
Neurology Blood Tests Primed to Improve Diagnosis, Management of Patients in Alzheimer's and Beyond
Premium
Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic mainstream.
Fujirebio, Eisai Partnering on Blood-based Biomarkers for Neurodegenerative Disease
The companies said they plan to explore a range of questions including the clinical implementation of the Alzheimer's disease biomarker phosphorylated tau 217.
Top Five Articles on 360Dx Last Week: Digital Pathology Adoption; FDA Reclassify Hep B Tests; More
Last week, readers were most interested in a story about whether digital pathology is approaching a breakout moment in its adoption curve.
Fujirebio Files Blood-Based Alzheimer's Test With FDA
The test measures levels of p-tau 217 and β-Amyloid 1-42 in human plasma to identify patients with the amyloid brain pathology characteristic of Alzheimer's disease.
Davos Alzheimer's Collaborative Creates Initiative to Improve Alzheimer's Diagnosis
Under the program, blood biomarkers and confirmatory diagnostic testing will be used to increase diagnosis of Alzheimer’s disease and related dementias.